Investigating novel treatments for a brighter tomorrow
See Enrolling StudiesClinical trials are carefully designed research studies that explore if a new medication or device is safe and effective for humans. These studies may also show which medical approaches work best for certain illnesses or groups of people.
Uptown Research Institute is currently enrolling patients in clinical trials for the following:
Anxiety Outpatient – MindMed-300
This study is designed to evaluate the efficacy of a single dose of 100 µg of MM-120 (D-lysergic acid diethylamide D-tartrate), versus placebo, for the treatment of anxiety symptoms.
This study is sponsored by Mind Medicine, Inc.
Depression Outpatient – MindMed-310
This study is designed to evaluate the efficacy of a single dose of 100 µg of MM-120 (D-lysergic acid diethylamide D-tartrate), versus placebo, for the treatment of depression symptoms.
This study is sponsored by Mind Medicine, Inc.
Depression Outpatient – Cybin 003-002
For adults with a diagnosis of Major Depressive Disorder (MDD) currently experiencing a Major Depressive Episode (MDE).
The goal of this study is to evaluate the efficacy, safety, and tolerability of CYB003 15 mg, compared to placebo, in treating symptoms of MDD in adult participants.
This study is sponsored by Cybin.
Learn MoreSchizophrenia Inpatient – Maplight-007C-MA
For adults with schizophrenia who warrant inpatient hospitalization.
The goal of this study is to assess the efficacy, safety, and tolerability of ML-007C-MA compared with placebo in reducing symptoms of schizophrenia in adults experiencing an acute exacerbation of psychosis.
This study is sponsored by Maplight Therapeutics.
Learn MoreSchizophrenia Inpatient – Neurocrine-3029
For adults with schizophrenia who warrant inpatient hospitalization.
The goal of this study is to assess the efficacy, safety, and tolerability of NBI-1117568 in adults with schizophrenia.
This study is sponsored by Neurocrine Biosciences, Inc.
Schizophrenia Inpatient – Otsuka-00035
Treatment for worsening of symptoms in patients with schizophrenia.
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of SEP-363856 (75 mg to 100 mg /daily) compared to a placebo in adults experiencing an acute exacerbation of schizophrenia.
This study is sponsored by Otsuka Pharmaceutical.
Learn MoreSchizophrenia Cognition Outpatient – Alto-101-201
For adults with cognitive impairment associated with symptoms of schizophrenia
The goal of this study is to evaluate the efficacy, safety, and tolerability of ALTO-101T (transdermal patches) versus placebo in normalizing EEG (electroencephalogram) cognitive processing markers and cognition itself.
This study is sponsored by Alto Neuroscience.
Learn MoreUptown Research Institute offers an array of clinical trials across a variety of psychiatric and medical conditions.
We follow ethical and legal guidelines to meet FDA requirements, protect patient volunteers, preserve the integrity of the study, and ensure privacy.
In order to participate in a clinical trial, patients must sign an Informed Consent Form. This document describes the rights and responsibilities for participants, including the voluntary nature of participation.
Criteria For Enrollment
Not every person can participate in a clinical trial. All clinical trials have guidelines regarding who can participate, such as:
Inclusion Criteria, or factors that allow someone to participate in a clinical research trial
Exclusion Criteria, or factors that exclude someone from participation in a clinical research trial
Inclusion and exclusion criteria may include factors like:
Age
Type and stage of disease
Previous treatment history
Other medical conditions